Susanne Wilke

Caring Deeply. Changing Lives. We measure success by our impact on patients we serve. Neurotrope BioScience, (OTCQB:NTRPD), formed in 2012, is at the forefront of the biotech industry and is focused on developing novel therapies with Bryostatin 1 for the treatment of neurodegenerative diseases and developmental disorders, initially focused on Alzheimer’s. We have a pipeline that includes various treatment approaches with Bryostatin 1 for serious and difficult-to-treat Orphan diseases, including Fragile X Syndrome (FXS) and Niemann-Pick Type C (NPC). Multi Modal Efficacy Bryostatin-1 activates Synaptic Growth Factors – BDNF, NGF, IGF, others. It also activates all amyloid-β Degrading Enzymes (ECE, Neprilysin, IDE). Bryostatin also activates α-secretase, which reduces formation of neurotoxic amyloid-β formed by γ-secretase and BACE. ApoE3 induces PKCϵ; by activating PKCϵ, so there is an increase in BDNF expression. Bryostatin blocks ApoE4's reduction of BDNF via HDAC inhibition. Bryostatin normalizes GSK3-β, thereby inhibiting pathological Tau protein transformation into neurofibrillary tangles (NFTs). Alzheimer’s disease Bryostatin is currently being tested in a 148 moderate to severe Alzheimer's disease patient population across 26 sites in the U.S. First patients dosed January 2016 and now fully enrolled. Primary efficacy endpoint based on Severe Impairment Battery Scale (SIB). Entry criteria based on the MMSE score. Top line data expected in April 2017. Fragile X Syndrome (FXS) is a devastating genetic disorder that causes developmental delays in children (135,000 U.S.), including developmental delays, intellectual and learning disabilities, anxiety, and autism spectrum disorders. In multiple FXS animal models it was shown that Bryostatin 1 improved memory and learning and behavior, the latter independently with the FRAXA Research Foundation. We plan to institute a Phase 2 clinical trial in FXS patients early next year.

Caring Deeply. Changing Lives. We measure success by our impact on patients we serve. Neurotrope BioScience, (OTCQB:NTRPD), formed in 2012, is at the forefront of the biotech industry and is focused on developing novel therapies with Bryostatin 1 for the treatment of neurodegenerative diseases and developmental disorders, initially focused on Alzheimer’s. We have a pipeline that includes various treatment approaches with Bryostatin 1 for serious and difficult-to-treat Orphan diseases, including Fragile X Syndrome (FXS) and Niemann-Pick Type C (NPC). Multi Modal Efficacy Bryostatin-1 activates Synaptic Growth Factors – BDNF, NGF, IGF, others. It also activates all amyloid-β Degrading Enzymes (ECE, Neprilysin, IDE). Bryostatin also activates α-secretase, which reduces formation of neurotoxic amyloid-β formed by γ-secretase and BACE. ApoE3 induces PKCϵ; by activating PKCϵ, so there is an increase in BDNF expression. Bryostatin blocks ApoE4's reduction of BDNF via HDAC inhibition. Bryostatin normalizes GSK3-β, thereby inhibiting pathological Tau protein transformation into neurofibrillary tangles (NFTs). Alzheimer’s disease Bryostatin is currently being tested in a 148 moderate to severe Alzheimer's disease patient population across 26 sites in the U.S. First patients dosed January 2016 and now fully enrolled. Primary efficacy endpoint based on Severe Impairment Battery Scale (SIB). Entry criteria based on the MMSE score. Top line data expected in April 2017. Fragile X Syndrome (FXS) is a devastating genetic disorder that causes developmental delays in children (135,000 U.S.), including developmental delays, intellectual and learning disabilities, anxiety, and autism spectrum disorders. In multiple FXS animal models it was shown that Bryostatin 1 improved memory and learning and behavior, the latter independently with the FRAXA Research Foundation. We plan to institute a Phase 2 clinical trial in FXS patients early next year.